,24 This is evident in the heterogeneity of tumour responses to PD-1 and BRAF inhibitors,25,26 and likely why predictive markers of immunotherapy response and resistance have large variation and limited specificity and performance.27 The gene discussed is BRAF; the disease is neoplasm.